Senti Bio Announces FDA Clearance of IND Application for SENTI-202 for the Treatment of Relapsed or Refractory Hematologic Malignancies Including Acute Myeloid Leukemia
– First patient in Phase 1 clinical trial expected to be treated in Q2 2024 –
– Initial clinical efficacy data expected by year-end 2024 and durability data expected in 2025 –
Related news for (SNTI)
- Breaking News: MoBot’s Latest Update as of 07/14/25 05:00 AM
- Don’t Miss Out: MoBot’s Latest Stock Updates 07/14/25 04:00 AM
- Don’t Miss Out: MoBot’s Latest Stock Updates 07/11/25 07:00 PM
- Senti Biosciences Announces New Employment Inducement Grants
- Senti Biosciences Announces New Employment Inducement Grants